Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
BioNexus Gene Lab Corp Common stock(BGLC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BGLC
11/10/2026: BGLC (1-star) is currently NOT-A-BUY. Pass it for now.
BioNexus Gene Lab Corp is a micro-cap biotechnology company that operates a dual-business model, combining clinical liquid biopsy diagnostics with a steady, traditional chemical trading segment in Southeast Asia. The company's main strength lies in its specialized RNA-based screening technology, which aims to address early disease detection needs. Its primary growth story centers on commercializing these genomic platforms while utilizing a significant equity financing facility to fund future expansion. However, the company faces high risks, including intense competition, potential share dilution, and the need for operational stability. It is best suited for speculative growth investors who can tolerate high volatility and closely monitor clinical and capital-raising milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company is in an early growth stage but carries significant risks associated with commercializing new medical technology. |
| Momentum investor | Strong fit while signal remains positive | The stock's high volatility and periodic news-driven spikes can provide short-term opportunities for those monitoring the trend. |
| Value investor | Weak fit | The company lacks stable, consistent earnings and high-quality fundamentals that typically attract value investors. |
| Dividend investor | Weak fit | BGLC does not pay dividends and focuses all capital on development and expansion. |
| Low-risk investor | Weak fit | The company's small-cap status, volatility, and industry risk profile are unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Thin trading volumes and small market cap lead to significant daily price swings. |
| Valuation risk | High | The stock price is often speculative rather than tied to consistent operational earnings. |
| Competition risk (Molecular Diagnostics) | High | BGLC competes against giants like Exact Sciences and Guardant Health with vastly larger resources. |
| Business quality | Low | The company is still proving its business model and operational reliability in the biotech space. |
| Dividend income | Low / none | Investors receive zero income from dividends, making total returns dependent on capital gains. |
| Execution risk | High | The complexity of balancing biotech commercialization with legacy chemical trading creates significant operational challenges. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -52.18% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.62M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 8.7K shares | Beta 1.97 | 52 Weeks Range 0.81 - 5.13 | Updated Date 11/10/2026 |
52 Weeks Range 0.81 - 5.13 | Updated Date 11/10/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.26 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Healthcare Diagnostics | Liquid biopsy and genomic screening services via MRNA Scientific. | Revenue comes from testing fees, but this is an early-stage growth segment. |
| Industrial Chemicals | Trading of polyester resins and raw materials via Chemrex. | Provides stable, albeit low-growth, operational cash flow for the company. |
| Geography (Southeast Asia) | Primary operations and markets in Malaysia, Indonesia, and Vietnam. | Exposure to emerging market economic trends and industrial growth. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value -888.19K | Price to Sales(TTM) 0.84 |
Enterprise Value -888.19K | Price to Sales(TTM) 0.84 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 629.53 | Shares Outstanding 2.93M | Shares Floating 1.67M |
Shares Outstanding 2.93M | Shares Floating 1.67M | ||
Percent Insiders 44.72 | Percent Institutions 0.5 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.